



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: May 8, 2006  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/092,934
Sheet 1 of 1		Filing Date	03/08/2002
		First Named Inventor	Paul Averback
		Group Art Unit	1643
		Examiner Name	Hong Sang
		Attorney Docket Number	018792-0199

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
HS	C 1	SHIROTA, K., et al., "Characterization of Novel Kidney-Specific Delivery System Using an Alkylglucoside Vector," <i>J. Pharmacology and Experimental Therapeutics</i> , vol. 299, no. 2, 2001, pp. 459-467.	
HS	C 2	ZHOU, S, et al., "Delivery of glucocorticoid conjugate in rat gastrointestinal tract and its treatment for ulcerative colitis," <i>Acta Pharmacol Sin</i> , 2001 Aug, 22(8), pp. 761-764.	
HS	C 3	ANTCZAK, C., et al., "A new acivicin prodrug designed for tumor-targeted delivery," <i>NCBI, PubMed Abstract of Bioorg Med Chem</i> 2001 Nov, 9(11):2843-8.	
HS	C 4	BRADLEY, M., et al., "Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel," <i>Clinical Cancer Research</i> , vol. 7, October 2001, pp. 3229-3238.	
HS	C 5	DOWELL, J.A., et al., "Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse," <i>NCBI, PubMed Abstract of J. Clin Pharmacol</i> , 2001, Nov., 41(11):1206-14.	
HS	C 6	KRATZ, F., et al., "Drug-polymer conjugates containing acid-cleavable bonds," <i>NCBI, PubMed Abstract of Crit Rev Ther Drug Carrier Syst.</i> , 1999, 16(3):245-88.	
HS	C 7	OHYA, Y., et al., "Design of macromolecular prodrug of cisplatin using dextran with branched galactose units as targeting moieties to hepatoma cells," <i>NCBI, PubMed Abstract of Biomacromolecules</i> , 2001 Fall, 2(3), 927-33.	
HS	C 8	SAWA, T., et al., "Tumor-targeting Chemotherapy by a Xanthine Oxidase-Polymer Conjugate That Generates Oxygen-free Radicals in Tumor Tissue," <i>Cancer Research</i> 60, February 1, 2001, pp. 666-671.	
HS	C 9	SCHASCHKE, N., et al., "Beta-cyclodextrin/epoxysuccinyl peptide conjugates: a new drug targeting system for tumor cells," <i>NCBI, PubMed Abstract of Bioorg Med Chem Lett</i> . 2000 Apr. 3; 10(7), 677-80.	
HS	C 10	SHIAH, J., et al., "Antitumor Activity of N-(2-Hydroxypropyl)methacrylamide Copolymer-Mesochlorin es and Adriamycin Conjugates in Combination Treatments," <i>Clinical Cancer Research</i> , vol. 6, March 2000, pp. 1008-1015.	

Examiner Signature	/Hong Sang/ (06/02/2006)	Date Considered	06/02/2006
--------------------	--------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH\_1596668.1